Immunotherapy with NK cells: recent developments in gene modification open up new avenues

References

• Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633–12. doi:10.1016/S1471-4906(01)02060-9.
   PubMed Web of Science ®Google Scholar
• Wang M, Windgassen D, Papoutsakis ET. Comparative analysis of transcriptional profiling of CD3+, CD4+ and CD8+ T cells identifies novel immune response players in T-cell activation. BMC Genomics. 2008;9(1):225. doi:10.1186/1471-2164-9-225.
   PubMed Web of Science ®Google Scholar
• Kruse PH, Matta J, Ugolini S, Vivier E. Natural cytotoxicity receptors and their ligands. Immunol Cell Biol. 2014;92(3):221–229. doi:10.1038/icb.2013.98.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SEA, Yagita H, Takeda K, Dommelen SLHV, Degli-Esposti MA, Hayakawa Y, et al. Activation of NK cell cytotoxicity. Mol Immunol. 2005;42(4):501–510. doi:10.1016/j.molimm.2004.07.034.
   PubMed Web of Science ®Google Scholar
• Luevano M, Daryouzeh M, Alnabhan R, Querol S, Khakoo S, Madrigal A, Saudemont A. The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol. 2012;73(3):248–257. doi:10.1016/j.humimm.2011.12.015.
   PubMed Web of Science ®Google Scholar
• Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res. 2001;10(4):535–544. doi:10.1089/15258160152509145.
   PubMedGoogle Scholar
• Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The broad spectrum of human natural killer cell diversity. Immunity. 2017;47(5):820–833. doi:10.1016/j.immuni.2017.10.008.
   PubMed Web of Science ®Google Scholar
• Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev. 2006;214(1):56–72. doi:10.1111/j.1600-065X.2006.00451.x.
   PubMedGoogle Scholar
• Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, Norris PJ, Nixon DF, Lanier LL. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood. 2010;116(19):3865–3874. doi:10.1182/blood-2010-04-282301.
   PubMed Web of Science ®Google Scholar
• Iannello A, Debbeche O, Samarani S, Ahmad A. Antiviral NK cell responses in HIV infection: I. NK cell receptor genes as determinants of HIV resistance and progression to AIDS. J Leukoc Biol. 2008;84(1):1–26. doi:10.1189/jlb.0907650.
   PubMed Web of Science ®Google Scholar
• Grievink HW, Luisman T, Kluft C, Moerland M, Malone KE. Comparison of three isolation techniques for human peripheral blood mononuclear cells: cell recovery and viability, population composition, and cell functionality. Biopreserv Biobank. 2016;14(5):410–415. doi:10.1089/bio.2015.0104.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4(4):330–336. doi:10.1038/ni904.
   PubMed Web of Science ®Google Scholar
• Pan Y, Tian T, Park CO, Lofftus SY, Mei S, Liu X, Luo C, O’Malley JT, Gehad A, Teague JE, et al. Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism. Nature. 2017;543(7644):252–256. doi:10.1038/nature21379.
   PubMed Web of Science ®Google Scholar
• Ribot JC, deBarros A, Pang DJ, Neves JF, Peperzak V, Roberts SJ, Girardi M, Borst J, Hayday AC, Pennington DJ, et al. CD27 is a thymic determinant of the balance between interferon-γ- and interleukin 17–producing γδ T cell subsets. Nat Immunol. 2009;10(4):427–436. doi:10.1038/ni.1717.
   PubMed Web of Science ®Google Scholar
• Kriegsmann K, Kriegsmann M, von Bergwelt-baildon M, Cremer M, Witzens-Harig M. NKT cells – new players in CAR cell immunotherapy? Eur J Haematol. 2018;101(6):750–757. doi:10.1111/ejh.13170.
   PubMed Web of Science ®Google Scholar
• Decaup E, Rossi C, Gravelle P, Laurent C, Bordenave J, Tosolini M, Tourette A, Perrial E, Dumontet C, Poupot M, et al. A tridimensional model for NK cell-mediated ADCC of follicular lymphoma. Front Immunol. 2019;10:1943. doi:10.3389/fimmu.2019.01943.
   PubMed Web of Science ®Google Scholar
• Freeman AJ, Vervoort SJ, Ramsbottom KM, Kelly MJ, Michie J, Pijpers L, Johnstone RW, Kearney CJ, Oliaro J. Natural killer cells suppress T cell-associated tumor immune evasion. Cell Rep. 2019;28(11):2784–94 e5. doi:10.1016/j.celrep.2019.08.017.
   PubMed Web of Science ®Google Scholar
• Mehta RS, Rezvani K. Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. Front Immunol. 2018;9:283. doi:10.3389/fimmu.2018.00283.
   PubMed Web of Science ®Google Scholar
• Iwaszko M, Bogunia-Kubik K. Clinical significance of the HLA-E and CD94/NKG2 interaction. Arch Immunol Ther Exp (Warsz). 2011;59(5):353–367. doi:10.1007/s00005-011-0137-y.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Cretney E, Kelly JM, Westwood JA, Shayna E A Street EA,  Yagita H, Takeda K,  van Dommelen LH,  Degli-Esposti MA,  Hayakawa Y. Activation of NK cell cytotoxicity. Mol Immunol. 2005;42(4):501–510. doi:10.1016/j.molimm.2004.07.034.
   PubMed Web of Science ®Google Scholar
• Algarra I, Garc�a-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother. 2010;17(10):147–154. doi:10.1007/s00262-004-0517-9.
   Google Scholar
• Bix M, Liao NS, Zijlstra M, Loring J, Jaenisch R, Raulet D. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature. 1991;349(6307):329–331. doi:10.1038/349329a0.
   PubMed Web of Science ®Google Scholar
• Costello RT, Gastaut JA, Olive D. Tumor escape from immune surveillance. Arch Immunol Ther Exp (Warsz). 1999;47:83–88.
   PubMedGoogle Scholar
• Kumar V, McNerney ME. A new self: MHC-class-I-independent Natural-killer-cell self-tolerance. Nat Rev Immunol. 2005;5(5):363–374. doi:10.1038/nri1603.
   PubMed Web of Science ®Google Scholar
• Ullrich E, Koch J, Cerwenka A, Steinle A. New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology. 2013;2(10):e26097. doi:10.4161/onci.26097.
   PubMed Web of Science ®Google Scholar
• Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, Mandelboim O. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol. 2001;31(9):2680–2689. doi:10.1002/1521-4141(200109)31:9<2680::AID-IMMU2680>3.0.CO;2-A.
   PubMed Web of Science ®Google Scholar
• Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni M, Umansky V, Paschen A, Sucker A, et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest. 2009;119(5):1251–1263. doi:10.1172/JCI36022.
   PubMed Web of Science ®Google Scholar
• Raulet DH, Vance RE. Self-tolerance of natural killer cells. Nat Rev Immunol. 2006;6(7):520–531. doi:10.1038/nri1863.
   PubMed Web of Science ®Google Scholar
• Brodin P, Kärre K, Höglund P. NK cell education: not an on-off switch but a tunable rheostat. Trends Immunol. 2009;30(4):143–149. doi:10.1016/j.it.2009.01.006.
   PubMed Web of Science ®Google Scholar
• Pradeu T, Vivier E. The discontinuity theory of immunity. Sci Immunol. 2016;1(1):AAG0479. doi:10.1126/sciimmunol.aag0479.
   PubMed Web of Science ®Google Scholar
• Bengsch B, Ohtani T, Herati RS, Bovenschen N, Chang KM, Wherry EJ. Deep immune profiling by mass cytometry links human T and NK cell differentiation and cytotoxic molecule expression patterns. J Immunol Methods. 2018;453:3–10. doi:10.1016/j.jim.2017.03.009.
   PubMed Web of Science ®Google Scholar
• Cheng M, Zhang J, Jiang W, Chen Y, Tian Z. Natural killer cell lines in tumor immunotherapy. Front Med. 2012;6(1):56–66. doi:10.1007/s11684-012-0177-7.
   PubMedGoogle Scholar
• Tang X, Yang L, Li Z, Nalin AP, Dai H, Xu T, Yin J, You F, Zhu M, Shen W, et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018;8(6):1083–1089.
   PubMed Web of Science ®Google Scholar
• Fang F, Xiao W, Tian Z. NK cell-based immunotherapy for cancer. Semin Immunol. 2017;31:37–54. doi:10.1016/j.smim.2017.07.009.
   PubMed Web of Science ®Google Scholar
• Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8:652–658.
   PubMed Web of Science ®Google Scholar
• Klingemann H, Boissel L, Toneguzzo F. Natural killer cells for immunotherapy – advantages of the NK-92 cell line over blood NK cells. Front Immunol. 2016;7:91. doi:10.3389/fimmu.2016.00091.
   PubMed Web of Science ®Google Scholar
• Antony GK, Dudek AZ. Interleukin 2 in cancer therapy. Curr Med Chem. 2010;17(29):3297–3302. doi:10.2174/092986710793176410.
   PubMed Web of Science ®Google Scholar
• Nham T, Poznanski SM, Fan IY, Vahedi F, Shenouda MM, Lee AJ, Chew MV, Hogg RT, Lee DA, Ashkar AA, et al. Ex vivo-expanded natural killer cells derived from long-term cryopreserved cord blood are cytotoxic against primary breast cancer cells. J Immunother. 2018;41(2):64–72. doi:10.1097/CJI.0000000000000192.
   PubMed Web of Science ®Google Scholar
• Spanholtz J, Tordoir M, Eissens D, Preijers F, van der Meer A, Joosten I, Schaap N, de Witte TM, Dolstra H, et al. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS One. 2010;5(2):e9221. doi:10.1371/journal.pone.0009221.
   PubMed Web of Science ®Google Scholar
• Mace EM, Orange JS. Genetic causes of human NK cell deficiency and their effect on NK cell subsets. Front Immunol. 2016;7. doi:10.3389/fimmu.2016.00545.
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, Perruccio K,  Shlomchik WD,  Tosti A,  Posati S,  Rogaia D,  Frassoni F,  Aversa F,   Martelli MF,  Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097. PMID: 11896281.  doi:10.1126/science.1068440.
   PubMed Web of Science ®Google Scholar
• Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol. 2008;9:486–494. doi:10.1038/ni1580.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. J Biol Response Mod. 1984;3:501–511.
   PubMedGoogle Scholar
• Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med. 2005;202(8):1075–1085. doi:10.1084/jem.20051511.
   PubMed Web of Science ®Google Scholar
• Granzin M, Wagner J, Köhl U, Cerwenka A, Huppert V, Ullrich E. Shaping of natural killer cell antitumor activity by ex vivo cultivation. Front Immunol. 2017;8. doi:10.3389/fimmu.2017.00458.
   PubMed Web of Science ®Google Scholar
• Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, et al. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood. 2018;131(23):2515–2527. doi:10.1182/blood-2017-12-823757.
   PubMed Web of Science ®Google Scholar
• Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, Carson WE. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor–positive tumor cells is enhanced by cytokines. Clin Cancer Res. 2007;13(21):6419. doi:10.1158/1078-0432.CCR-07-0865.
   PubMed Web of Science ®Google Scholar
• Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, Polimeni M, Spadi R, Donadio M, Ciuffreda L, Matera L, et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med. 2008;6(1):25. doi:10.1186/1479-5876-6-25.
   PubMedGoogle Scholar
• Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14(14):4650. doi:10.1158/1078-0432.CCR-07-4405.
   PubMed Web of Science ®Google Scholar
• Felices M, Lenvik TR, Davis ZB, Miller JS, Vallera DA. Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells. Methods Mol Biol. 2016;1441:333–346.
   PubMedGoogle Scholar
• Benson DM Jr., Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116(13):2286–2294. doi:10.1182/blood-2010-02-271874.
   PubMed Web of Science ®Google Scholar
• Khan M, Arooj S, Wang H. NK cell-based immune checkpoint inhibition. Front Immunol. 2020;11:167.
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 2011;17(19):6287–6297. doi:10.1158/1078-0432.CCR-11-1347.
   PubMed Web of Science ®Google Scholar
• Sakamoto N, Ishikawa T, Kokura S, Okayama T, Oka K, Ideno M, Sakai F, Kato A, Tanabe M, Enoki T. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J Transl Med. 2015;13(1):277. doi:10.1186/s12967-015-0632-8.
   PubMedGoogle Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051–3057. doi:10.1182/blood-2004-07-2974.
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Ribeiro RC, Jeffrey E. Rubnitz , Hiroto Inaba , Raul C. Ribeiro ,  Pounds S , Rooney B ,  BellChing-Hon Pui T ,  Leung W. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28(6):955–959. doi:10.1200/JCO.2009.24.4590.
   PubMed Web of Science ®Google Scholar
• Shaffer BC, Le Luduec JB, Forlenza C, Jakubowski AA, Perales M-A, Young JW, Hsu KC. Phase II study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(4):705–709. doi:10.1016/j.bbmt.2015.12.028.
   PubMed Web of Science ®Google Scholar
• Shah NN, Baird K, Delbrook CP, Fleisher TA, Kohler ME, Rampertaap S, Lemberg K, Hurley CK, Kleiner DE, Merchant MS, et al. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell–depleted stem cell transplantation. Blood. 2015;125(5):784–792. doi:10.1182/blood-2014-07-592881.
   PubMed Web of Science ®Google Scholar
• Lupo KB, Matosevic S. Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy. Cancers (Basel). 2019;11(6):769. doi:10.3390/cancers11060769.
   PubMed Web of Science ®Google Scholar
• Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, Leong JW, Abdel-Latif S, Schneider SE, Willey S, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357):357ra123. doi:10.1126/scitranslmed.aaf2341.
   PubMed Web of Science ®Google Scholar
• Williams BA, Law AD, Routy B, denHollander N, Gupta V, Wang X-H, Chaboureau A, Viswanathan S, Keating A. A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarget. 2017;8(51):89256–89268. doi:10.18632/oncotarget.19204.
   PubMedGoogle Scholar
• Ciurea SO, Schafer JR, Bassett R, Denman CJ, Cao K, Willis D, Rondon G, Chen J, Soebbing D, Kaur I, et al. Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017;130(16):1857–1868. doi:10.1182/blood-2017-05-785659.
   PubMed Web of Science ®Google Scholar
• Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168(4):724–740. doi:10.1016/j.cell.2017.01.016.
   PubMed Web of Science ®Google Scholar
• You F, Wang Y, Jiang L, Zhu X,  Chen D,  Yuan L,  An G,  Meng H,  Yang L. A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. Am J Cancer Res. 2019;9(1):64–78. eCollection 2019. PMID: 30755812 PMCID: PMC6356925.
   PubMed Web of Science ®Google Scholar
• Duan H, Huang H, Jing G. An antibody fab fragment-based chimeric antigen receptor could efficiently eliminate human thyroid cancer cells. J Cancer. 2019;10(8):1890–1895. doi:10.7150/jca.30163.
   PubMed Web of Science ®Google Scholar
• Balakrishnan A, Rajan A, Salter AI, Kosasih PL, Wu Q, Voutsinas J, Jensen MC, Plückthun A, Riddell SR. Multispecific targeting with synthetic ankyrin repeat motif chimeric antigen receptors. Clin Cancer Res. 2019;25(24):7506. doi:10.1158/1078-0432.CCR-19-1479.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014;257:83–90. doi:10.1111/imr.12125.
   PubMed Web of Science ®Google Scholar
• Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, Corder A, Schönfeld K, Koch J, Dotti G, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids. 2013;2:e105. doi:10.1038/mtna.2013.32.
   PubMedGoogle Scholar
• Roybal KT, Rupp LJ, Morsut L, Walker W, McNally K, Park J, Lim W. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016;164(4):770–779. doi:10.1016/j.cell.2016.01.011.
   PubMed Web of Science ®Google Scholar
• Fedorov VD, Themeli M, Sadelain M. PD-1– and CTLA-4–based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5(215):215ra172. doi:10.1126/scitranslmed.3006597.
   PubMed Web of Science ®Google Scholar
• Grote S, Chan C-H, Baden C, Huber SM, Eckert F,  Mittelstaet J, Kaiser A,  Seitz C,  Schlegel P,  Handgretinger R and  Schleicher S. Abstract B70: universal adapter CAR-engineered NK-92 cells target patient-derived glioblastoma cancer stem cells. Cancer Immunol Res. 2020;8:B70.doi: 10.1158/2326-6074.TUMIMM19-B70. Published March 2020
   PubMed Web of Science ®Google Scholar
• Seitz CM, Kieble V, Illi C, Reiter S, Grote S, Mittelstaet J, Lock D, Kaiser A, Schleicher S, Handgretinger R, et al. Combinatorial targeting of multiple shared antigens by adapter-CAR-T Cells (aCAR-Ts) allows target cell discrimination and specific lysis based on differential expression profiles. Blood. 2018;132(Supplement 1):4543. doi:10.1182/blood-2018-99-115630.
   Google Scholar
• Matosevic S. Viral and nonviral engineering of natural killer cells as emerging adoptive cancer immunotherapies. J Immunol Res. 2018;2018:4054815. doi:10.1155/2018/4054815.
   PubMed Web of Science ®Google Scholar
• Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013;73(6):1777–1786. doi:10.1158/0008-5472.CAN-12-3558.
   PubMed Web of Science ®Google Scholar
• Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106(1):376–383. doi:10.1182/blood-2004-12-4797.
   PubMed Web of Science ®Google Scholar
• Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520–531. doi:10.1038/leu.2017.226.
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, Clappier E, Caccavelli L, Delabesse E, Beldjord K, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132–3142. doi:10.1172/JCI35700.
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Von Kalle C, Schmidt M, S Hacein-Bey-Abina1, C Von Kalle, M Schmidt,  McCormack MP,  Wulffraat N,  Leboulch P, Lim A,  Osborne CS,  Pawliuk R, E Morillon E, &, Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415–419. PMID: 14564000 . doi:10.1126/science.1088547.
   PubMed Web of Science ®Google Scholar
• Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman MH, Schambach A, Charrier S, Galy A, Thrasher AJ, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther. 2009;17(11):1919–1928. doi:10.1038/mt.2009.179.
   PubMed Web of Science ®Google Scholar
• Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M, Benedicenti F, Sergi LS, Ambrosi A, Ponzoni M, et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest. 2009;119(4):964–975. doi:10.1172/JCI37630.
   PubMed Web of Science ®Google Scholar
• Rezvani K, Rouce R, Liu E, Shpall E. Engineering natural killer cells for cancer immunotherapy. Mol Ther. 2017;25(8):1769–1781. doi:10.1016/j.ymthe.2017.06.012.
   PubMed Web of Science ®Google Scholar
• Boissel L, Betancur M, Lu W, Wels WS, Marino T, Van Etten RA, Klingemann H. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leuk Lymphoma. 2012;53(5):958–965. doi:10.3109/10428194.2011.634048.
   PubMed Web of Science ®Google Scholar
• Suerth JD, Morgan MA, Kloess S, Heckl D, Neudörfl C, Falk CS, Koehl U, Schambach A. Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors. J Mol Med (Berl). 2016;94(1):83–93. doi:10.1007/s00109-015-1327-6.
   PubMed Web of Science ®Google Scholar
• Kloss S, Oberschmidt O, Morgan M, Dahlke J, Arseniev L, Huppert V, Granzin M, Gardlowski T, Matthies N, Soltenborn S, et al. Optimization of human NK cell manufacturing: fully automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of anti-CD123-CAR-expressing effector cells. Hum Gene Ther. 2017;28(10):897–913. doi:10.1089/hum.2017.157.
   PubMed Web of Science ®Google Scholar
• Oberschmidt O, Morgan M, Huppert V, Kessler J, Gardlowski T, Matthies N, Aleksandrova K, Arseniev L, Schambach A, Koehl U, et al. Development of automated separation, expansion, and quality control protocols for clinical-scale manufacturing of primary human NK cells and alpharetroviral chimeric antigen receptor engineering. Hum Gene Ther Methods. 2019;30(3):102–120. doi:10.1089/hgtb.2019.039.
   PubMed Web of Science ®Google Scholar
• Kaufmann KB, Brendel C, Suerth JD, Mueller-Kuller U, Chen-Wichmann L, Schwäble J, Pahujani S, Kunkel H, Schambach A, Baum C, et al. Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing. Mol Ther. 2013;21(3):648–661. doi:10.1038/mt.2012.249.
   PubMed Web of Science ®Google Scholar
• Suerth JD, Maetzig T, Brugman MH, Heinz N, Appelt J-U, Kaufmann KB, Schmidt M, Grez M, Modlich U, Baum C, et al. Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity. Mol Ther. 2012;20(5):1022–1032. doi:10.1038/mt.2011.309.
   PubMed Web of Science ®Google Scholar
• Müller S, Bexte T, Gebel V, Kalensee F, Stolzenberg E, Hartmann J, Koehl U, Schambach A, Wels WS, Modlich U, et al. High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia. Front Immunol. 2020;10. doi:10.3389/fimmu.2019.03123
   Web of Science ®Google Scholar
• Bari R, Granzin M, Tsang KS, Roy A,  Krueger W,  Orentas R,  Schneider D,  Pfeifer R,  Moeker N,  Verhoeyen E,   Dropulic B and  Leung W. A distinct subset of highly proliferative and lentiviral vector (LV)-Transducible NK cells define a readily engineered subset for adoptive cellular therapy. Front Immunol. 2019;10. doi:10.3389/fimmu.2019.02001
   Web of Science ®Google Scholar
• Campbell KS, Dessing M, Lopez-Botet M, Cella M, Colonna M. Tyrosine phosphorylation of a human killer inhibitory receptor recruits protein tyrosine phosphatase 1C. J Exp Med. 1996;184(1):93–100. doi:10.1084/jem.184.1.93.
   PubMed Web of Science ®Google Scholar
• Swaney WP, Sorgi FL, Bahnson AB, Barranger JA. The effect of cationic liposome pretreatment and centrifugation on retrovirus-mediated gene transfer. Gene Ther. 1997;4(12):1379–1386. doi:10.1038/sj.gt.3300529.
   PubMed Web of Science ®Google Scholar
• Lowe E, Truscott LC, De Oliveira SN. In vitro generation of human NK cells expressing chimeric antigen receptor through differentiation of gene-modified hematopoietic stem cells. In: Somanchi SS, editor. Natural killer cells: methods and protocols. New York: Springer New York; 2016. p. 241–251.
   Google Scholar
• Fenard D, Ingrao D, Seye A, Buisset J, Genries S, Martin S, Kichler A, Galy A. Vectofusin-1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells. Mol Ther Nucleic Acids. 2013;2:e90. doi:10.1038/mtna.2013.17.
   PubMedGoogle Scholar
• Chang Y-H, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013;73(6):1777. doi:10.1158/0008-5472.CAN-12-3558.
   PubMed Web of Science ®Google Scholar
• Jiang H, Zhang W, Shang P, Zhang H, Fu W, Ye F, Zeng T, Huang H, Zhang X, Sun W, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol. 2014;8(2):297–310. doi:10.1016/j.molonc.2013.12.001.
   PubMed Web of Science ®Google Scholar
• Phatarpekar PV, Lee DA, Somanchi SS. Electroporation of siRNA to silence gene expression in primary NK cells. In: Somanchi SS, editor. Natural killer cells: methods and protocols. New York: Springer New York; 2016. p. 267–276.
   Google Scholar
• Maasho K, Marusina A, Reynolds NM, Coligan JE, Borrego F. Efficient gene transfer into the human natural killer cell line, NKL, using the Amaxa nucleofection system™. J Immunol Methods. 2004;284(1–2):133–140. doi:10.1016/j.jim.2003.10.010.
   PubMed Web of Science ®Google Scholar
• El Sobky SA, El-Ekiaby NM, Mekky RY, Elemam NM, Mohey Eldin MA, El-sayed M, Esmat G, Abdelaziz AI. Contradicting roles of miR-182 in both NK cells and their host target hepatocytes in HCV. Immunol Lett. 2016;169:52–60. doi:10.1016/j.imlet.2015.10.013.
   PubMed Web of Science ®Google Scholar
• Zhang J, Sun R, Wei H, Zhang J, Tian Z. Characterization of stem cell factor gene-modified human natural killer cell line, NK-92 cells: implication in NK cell-based adoptive cellular immunotherapy. Oncol Rep. 2004;11:1097–1106.
   PubMed Web of Science ®Google Scholar
• Somanchi SS, Somanchi A, Cooper LJN, Lee DA. Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood. 2012;119(22):5164–5172. doi:10.1182/blood-2011-11-389924.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Kuroi M, Fujiwara Y, Warashina S, Sato Y, Harashima H. Small-sized, stable lipid nanoparticle for the efficient delivery of siRNA to human immune cell lines. Sci Rep. 2016;6(1):37849. doi:10.1038/srep37849.
   PubMedGoogle Scholar
• Oyer JL, Pandey V, Igarashi RY, Somanchi SS, Zakari A, Solh M, Lee DA, Altomare DA, Copik AJ. Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: clinical implications for cancer treatment. Cytotherapy. 2016;18(5):653–663. doi:10.1016/j.jcyt.2016.02.006.
   PubMed Web of Science ®Google Scholar
• Daher M, Basar R, Shaim H, Gokdemir, E,  Uprety, N,  Kontoyiannis, A,  Carolina Mendt M, Imahashi N.... & Rezvani K  The TGF-β/SMAD signaling pathway as a mediator of NK cell dysfunction and immune evasion in myelodysplastic syndrome. Blood. 2017;130 (Supplement 1): 53.https://doi.org/10.1182/blood.V130.Suppl_1.53.53.
   Web of Science ®Google Scholar
• Dong G, Li Y, Jiang B, Yee J-K, Lee DA, McKeithan TW, Chan WC. Generation of natural killer cell lymphoma models in vitro by gene editing. Blood. 2016;128(22):2724. doi:10.1182/blood.V128.22.2724.2724.
   Web of Science ®Google Scholar
• Liu JH, Wei S, Blanchard DK, Djeu JY. Restoration of lytic function in a human natural killer cell line by gene transfection. Cell Immunol. 1994;156(1):24–35. doi:10.1006/cimm.1994.1150.
   PubMed Web of Science ®Google Scholar
• Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res. 2009;33(9):1255–1259. doi:10.1016/j.leukres.2008.11.024.
   PubMed Web of Science ®Google Scholar
• Li L, Liu LN, Feller S, Allen C, Shivakumar R, Fratantoni J, Wolfraim LA, Fujisaki H, Campana D, Chopas N, et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther. 2010;17(3):147–154. doi:10.1038/cgt.2009.61.
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Fujisaki H, Cho D, Masselli M, Lockey T, Eldridge P, Leung W, Campana D. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy. 2012;14(7):830–840. doi:10.3109/14653249.2012.671519.
   PubMed Web of Science ®Google Scholar
• Trompeter H-I, Weinhold S, Thiel C, Wernet P, Uhrberg M. Rapid and highly efficient gene transfer into natural killer cells by nucleofection. J Immunol Methods. 2003;274(1–2):245–256. doi:10.1016/S0022-1759(02)00431-3.
   PubMed Web of Science ®Google Scholar
• Somanchi SS, Denman CJ, Amritkar A, Senyukov V, Olivares S, Cooper LJN, Lee DA. Gene modification of human primary natural killer cells by electroporation with mRNA or DNA coding for an anti-GD2 chimeric antigen receptor. Blood. 2009;114(22):2467. doi:10.1182/blood.V114.22.2467.2467.
   PubMed Web of Science ®Google Scholar
• Elmacken M, Awasthi A, Ayello J, van de Ven C, Luo W, Liao Y, Riddell S, Cairo MS. Neuroblastoma and ewing’s sarcoma associated with ROR1 expression can be effectively targeted with NK cells modified to express an anti ROR1 chimeric antigen receptor. Biol Blood Marrow Transplant. 2015;21(2):S95–S7. doi:10.1016/j.bbmt.2014.11.117.
   Web of Science ®Google Scholar
• Liu H, Yang B, Sun T, Lin L, Hu Y, Deng M, Yang J, Liu T, Li J, Sun S, et al. Specific growth inhibition of ErbB2expressing human breast cancer cells by genetically modified NK92 cells. Oncol Rep. 2015;33(1):95–102. doi:10.3892/or.2014.3548.
   PubMed Web of Science ®Google Scholar
• Chu Y, Hochberg J, Yahr A, Ayello J, van de Ven C, Barth M, Czuczman M, Cairo MS. Targeting CD20+ aggressive b-cell non-hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice. Cancer Immunol Res. 2015;3(4):333–344. doi:10.1158/2326-6066.CIR-14-0114.
   PubMed Web of Science ®Google Scholar
• Wang J, Lupo KB, Chambers AM, Matosevic S. Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells. J ImmunoTher Cancer. 2018;6(1):136. doi:10.1186/s40425-018-0441-8.
   PubMed Web of Science ®Google Scholar
• Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181–92.e5. doi:10.1016/j.stem.2018.06.002.
   PubMed Web of Science ®Google Scholar
• Carlsten M, Levy E, Karambelkar A, Li L, Reger R, Berg M, Peshwa MV, Childs RW. Efficient mRNA-based genetic engineering of human NK cells with high-affinity CD16 and CCR7 augments rituximab-induced ADCC against lymphoma and targets NK cell migration toward the lymph node-associated chemokine CCL19. Front Immunol. 2016;7:105. doi:10.3389/fimmu.2016.00105.
   PubMed Web of Science ®Google Scholar
• Levy ER, Carlsten M, Childs RW. mRNA transfection to improve NK cell homing to tumors. In: Somanchi SS, editor. Natural killer cells: methods and protocols. New York: Springer New York; 2016. p. 231–240.
   Google Scholar
• Levy ER, Carlsten M, Childs RW. mRNA transfection to improve NK cell homing to tumors. Methods Mol Biol. 2016;1441:231–240.
   PubMedGoogle Scholar
• Hartmann J, Schussler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9(9):1183–1197. doi:10.15252/emmm.201607485.
   PubMed Web of Science ®Google Scholar
• Schonfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bönig H, Köhl U, Kloess S, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther. 2015;23(2):330–338. doi:10.1038/mt.2014.219.
   PubMed Web of Science ®Google Scholar
• Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545–553. doi:10.1056/NEJMoa1910607.
   PubMed Web of Science ®Google Scholar
• Xiao L, Cen D, Gan H, Sun Y, Huang N, Xiong H, Jin Q, Su L, Liu X, Wang K, et al. Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. Mol Ther. 2019;27(6):1114–1125. doi:10.1016/j.ymthe.2019.03.011.
   PubMed Web of Science ®Google Scholar